iScan 80 OCT to launch in UK

Article

According to Haag-Streit UK, the iScan80 is a high-speed OCT system ideal for practices seeking an affordable and versatile OCT system.

Haag-Streit UK’s iScan80 offers a fully integrated system which includes a full suite of retina, optic nerve and anterior segment scans. (Image courtesy of Haag-Streit UK)

Haag-Streit UK’s iScan80 offers a fully integrated system which includes a full suite of retina, optic nerve and anterior segment scans. (Image courtesy of Haag-Streit UK)

Haag-Streit UK (HS-UK) is launching its Optovue iScan80 in the UK.

According to the company, a manufacturer and distributor of orthoptic, optometry and ophthalmic equipment, the iScan80 is a high-speed OCT system ideal for practices seeking an affordable and versatile OCT system.

The iScan80 now delivers high-speed 80kHz OCT at 80,000 A-scans per second, 3 times faster than the original iScan system. It offers a more simplified scan acquisition, and a wider field of view.

Compact and portable, the iScan80’s streamlined design integrates the operator interface, display, patient interface and scan head into one console, making it ideal for small spaces. The tabletop design offers the flexibility to place it in any room, or transfer from one practice to another.

The company noted the iScan80 offers a range of fantastic features, including an OCT iWellness scan, retina mapping, RNFL and Ganglion Cell Complex trend analysis, high-density 3D retinal imaging and in-depth 3D optic nerve head analysis. It also boasts a comprehensive range of anterior scans, including; pachymetry, epithelial mapping, angle scans and vault mapping.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.